PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
March 23, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported...
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
February 16, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus
February 01, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
January 12, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Publication of Research Data for KETABET™
January 04, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of...
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022
December 21, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022 include initiating Phase 3 clinical study for...
PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch
December 20, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO and ANDERNACH, Germany, Dec. 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
December 14, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
Delivering LSD via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectivenessPursuing Phase 2 clinical studies in 2022 with LSD and...
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
November 30, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
November 24, 2021 07:30 ET
|
PharmaTher Holdings Ltd.
Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening...